Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 1/2014

Open Access 01-01-2014 | Case Report

Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab

Authors: A. Neuprez, S. Coste, E. Rompen, J. M. Crielaard, J. Y. Reginster

Published in: Osteoporosis International | Issue 1/2014

Login to get access

Abstract

Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the receptor activator of nuclear factor kappa-B ligand. It prevents osteoclast-mediated bone resorption and is widely prescribed for the management of postmenopausal osteoporosis. Whereas ONJ has already been reported in women treated with DMab, we report for the first time the development of ONJ, following tooth extraction, in a male patient treated for idiopathic osteoporosis with DMab. Due to the constant increase in DMab prescription, for the management of osteoporosis, in both genders, physicians should be made aware of this potential risk.
Literature
1.
Kaufman JM, Reginster JY, Boonen S, Brandi ML, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, Kanis JA, McCloskey E, Mitlak B, Orwoll E, Ringe JD, Weryha G, Rizzoli R (2013) Treatment of osteoporosis in men. Bone 53:134–144PubMedCentralPubMedCrossRef
2.
Kaufman JM, Goemaere S (2008) Osteoporosis in men. Best Pract Res Clin Endocrinol Metab 22:787–812PubMedCrossRef
3.
Rizzoli R, Boonen S, Brandi ML, Bruyère O, Cooper C, Kanis JA, Kaufman JM, Ringe JD, Weryha G, Reginster JY (2013) Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 29:305–313PubMedCrossRef
4.
Cavalier E, Delanaye P, Moranne O (2013) Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis : implications for clinical decision making. Am J Kindey Dis 61:847–848CrossRef
5.
Johansson H, Kanis JA, McCloskey EV, Oden A, Devogelaer JP, Kaufman JM, Neuprez A, Hiligsmann M, Bruyère O, Reginster JY (2011) A FRAX° model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–461PubMedCrossRef
6.
Neuprez A, Johansson H, Kanis JA, McCloskey EV, Oden A, Bruyère O, Hiligsmann M, Devogelaer JP, Kaufman JM, Reginster JY (2009) A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liège 64:612–619PubMed
7.
Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059–1066PubMedCrossRef
8.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57PubMedCentralPubMedCrossRef
9.
Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren O, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97:3161–3169PubMedCrossRef
10.
Parthan A, Kruse MM, Agodoa I, Tao CY, Silverman SL, Orwoll E (2013) Is denosumab cost-effective compared to oral bisphosphonates for the treatment of male osteoporosis (mop) in Sweden? Value Health 16:A223CrossRef
11.
Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42:841–847PubMedCrossRef
12.
Ruggiera SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534CrossRef
13.
Subramanian G, Cohen HV, Quek SY (2011) A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide’s potential role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:744–753PubMedCrossRef
14.
15.
Raylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 48:221–223CrossRef
16.
Diz P, Lopez-Cedrun JL, Arenaz J, Scully C (2012) Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc 143:981–984PubMedCrossRef
17.
Pichardo SE, Kuypers SC, Van Merkesteyn JP (2013) Denosumab osteonecrosis of the mandible: a new entity? A case report. J Craniomaxillofac Surg 41:e65–e69PubMedCrossRef
18.
Qi WX, Tang LN, He AN, Yao Y (2013) Shen Z Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol (in press)
19.
Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Man Z, Mellström D, Radominski SC, Reginster JY, Resch H, Roman Ivorra JA, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701PubMedCentralPubMedCrossRef
Metadata
Title
Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
Authors
A. Neuprez
S. Coste
E. Rompen
J. M. Crielaard
J. Y. Reginster
Publication date
01-01-2014
Publisher
Springer London
Published in
Osteoporosis International / Issue 1/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2437-z

Other articles of this Issue 1/2014

Osteoporosis International 1/2014 Go to the issue

Original Article

Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial

Original Article

An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide

Original Article

The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease

Original Article

Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study

Original Article

Association between hypertension and fragility fracture: a longitudinal study

Original Article

Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial